BioNexus Gene Lab 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Lee Tan

최고 경영자

US$16.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

Feb 14

CEO

Lee Tan (41 yo)

less than a year

테뉴어

US$16,000

보상

Mr. Su-Leng Tan, also known as Lee, is CEO & Director of BioNexus Gene Lab Corp. from December 11, 2023 and also serves as its Acting Chief Financial Officer and Secretary. Mr. Tan was Chief Operating Offi...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Su-Leng Tan	CEO, Acting CFO	less than a year	US$16.00k	데이터 없음
Chee Yap	Independent Non-Executive Director	2.7yrs	US$3.00k	데이터 없음
Muhammad bin Abdul Hamid	Independent Director	less than a year	데이터 없음	데이터 없음

0.9yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: BGLC 의 이사회는 경험(평균 재직 기간 0.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

BioNexus Gene Lab 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee

BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer

Recent updates

BioNexus Gene Lab Corp. announced delayed 10-Q filing

BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting Determination

Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee

BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024

Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)

High number of new and inexperienced directors

The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)

BioNexus Gene Lab Corp. announced delayed annual 10-K filing

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

High number of new and inexperienced directors

Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp

BioNexus Gene Lab Corp. announced delayed 10-Q filing

BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)

High number of new and inexperienced directors

BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer

BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer

BioNexus Gene Lab Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)

New minor risk - Shareholder dilution

High number of new and inexperienced directors

BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.

Bionexus Gene Lab Corporation Announces Management Changes

BioNexus Gene Lab Corporation announced delayed annual 10-K filing

BioNexus Gene Lab Corporation announced delayed 10-Q filing

BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령